/XRTX.V

XRTX.V Stock - XORTX Therapeutics Inc.

Q: What is the analyst price target for XRTX.V?

Analyst price target information is not currently available for XRTX.V.

Q: What is XRTX.V's market cap?

Market capitalization information is not currently available for XRTX.V.

Healthcare|Biotechnology|TSXV

$0.85+0.00%

+$0.00 (+0.00%) • Dec 16

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.94

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for XRTX.V

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.10

52W High$2.49

52W Low$0.76

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-160,660	$-141,958.87	$-75,268	$-17,882	$-20,439
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-5,641,938	$-4,805,077.3	$-12,433,624	$-2,902,877.83	$-1,082,239
Net Income	$-4,539,156	$-2,859,371.38	$-6,988,880.784	$-1,652,282	$-1,284,602
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-1.58	$-1.44	$-4.72	$-1.20	$-1.73

Company Overview

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.

Visit Website

Earnings History & Surprises

XRTX.V

Beat Rate

79%

Last 14 quarters

Avg Surprise

+426.4%

EPS vs Estimate

Beats / Misses

11/3

Last 12 quarters

Latest EPS

$-0.18

Q4 2025

EPS Surprise History

Q4 23

-156.5%

$-0.67vs$-0.26

Q2 24

-38.7%

$-1.24vs$-0.90

Q2 24

No data

Q3 24

+108.5%

$0.06vs$-0.69

Q4 24

+61.0%

$-0.20vs$-0.52

Q1 25

+86.2%

$-0.06vs$-0.42

Q3 25

+44.3%

$-0.19vs$-0.34

Q4 25

+41.6%

$-0.18vs$-0.32

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 13, 2026	—	—	—	—
Q4 2025	Nov 15, 2025	$-0.32	$-0.18	+41.6%	✓ BEAT
Q3 2025	Aug 14, 2025	$-0.34	$-0.19	+44.3%	✓ BEAT
Q1 2025	Mar 31, 2025	$-0.42	$-0.06	+86.2%	✓ BEAT
Q1 2025	Mar 25, 2025	$-0.42	—	—	—
Q4 2024	Nov 14, 2024	$-0.52	$-0.20	+61.0%	✓ BEAT
Q3 2024	Aug 14, 2024	$-0.69	$0.06	+108.5%	✓ BEAT
Q2 2024	Apr 19, 2024	—	$1.35	—	—
Q2 2024	Apr 3, 2024	$-0.90	$-1.24	-38.7%	✗ MISS
Q4 2023	Nov 14, 2023	$-0.26	$-0.67	-156.5%	✗ MISS
Q3 2023	Aug 15, 2023	$-0.25	$-0.12	+52.0%	✓ BEAT
Q2 2023	Apr 1, 2023	$-0.27	$-0.20	+25.9%	✓ BEAT
Q4 2022	Dec 31, 2022	$-2.95	$-1.84	+37.8%	✓ BEAT
Q4 2022	Nov 10, 2022	$-2.13	$-0.83	+61.0%	✓ BEAT
Q3 2022	Aug 11, 2022	$-0.24	$-0.12	+50.0%	✓ BEAT
Q2 2022	May 13, 2022	$-0.19	$-0.26	-36.8%	✗ MISS
Q2 2022	Apr 12, 2022	$-0.12	$6.64	+5633.3%	✓ BEAT
Q4 2021	Nov 29, 2021	—	$-8.00	—	—
Q3 2021	Aug 27, 2021	—	$-0.21	—	—
Q2 2021	May 31, 2021	—	$-2.38	—	—

Frequently Asked Questions about XRTX.V

What is XRTX.V's current stock price?

XORTX Therapeutics Inc. (XRTX.V) is currently trading at $0.85 per share. The stock has moved +0.00% today.

What is the analyst price target for XRTX.V?

No analyst price targets are currently available for this stock.

What sector is XORTX Therapeutics Inc. in?

XORTX Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the TSXV exchange.

What is XRTX.V's market cap?

XORTX Therapeutics Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does XRTX.V pay dividends?

No, XORTX Therapeutics Inc. does not currently pay a dividend to shareholders.